LA JOLLA, Calif., Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET.A li ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to s Commission File Number 001-39538 CalciMedica, Inc. (Exact name of Registrant as specified in its Charter) Delaware 45-2120079 (State or other jurisdiction ...

Productive initial meeting with the FDA on Auxora in acute pancreatitis (AP); conversations continue, with alignment on a pivotal trial anticipated around the end of 2025 Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., August 12, 2025 – CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and imm ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute pancreatitis (AP); conversations continue, with alignment on a pivotal trial anticipated around the end of 2025 Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., Aug. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutica ...

LA JOLLA, Calif., July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025, at 2:0 ...

Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc analysis of patients in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia who had AKI with respiratory failure at enrollmentLA JOLLA, Calif., June 25, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition t ...

LA JOLLA, Calif., June 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, It ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciMedica, Inc. (Exact name of Registrant as specified in its Charter) Delaware 45-2120079 (State or other jurisdiction ...

临床试验进展 - 公司预计在2025年底完成2期KOURAGE试验的患者入组，计划入组150人[4] - 2期CARDEA试验中AKI患者的事后分析显示，与安慰剂相比，Auxora的死亡率相对降低62.7%，绝对降低29.3% [1][5] 信贷安排 - 2025年3月5日，公司宣布与Avenue Venture Opportunities Fund II, L.P.达成信贷安排，最高可提供3250万美元[8] 资金状况 - 截至2025年3月31日，公司现金、现金等价物和短期投资为2460万美元，预计资金可支持运营至2026年年中[11] 研发费用变化 - 2025年第一季度研发费用为420万美元，2024年同期为290万美元，增加130万美元[11] 一般及行政费用变化 - 2025年第一季度一般及行政费用为230万美元，2024年同期为280万美元，减少50万美元[15] 其他收入变化 - 2025年第一季度其他收入为150万美元，2024年同期为590万美元，减少440万美元[15] 净亏损情况 - 2025年第一季度净亏损为590万美元，2024年同期净收入为10万美元[15] 资产负债情况 - 截至2025年3月31日，公司总资产为2534.7万美元，总负债为1445.9万美元[19] 每股收益变化 - 2025年第一季度每股基本亏损为0.36美元，2024年同期每股基本收益为0.01美元[21]

文章核心观点 - 临床阶段生物制药公司CalciMedica宣布首席执行官将在会议上演讲，介绍公司情况及产品研发进展 [1][3] 公司活动 - 公司首席执行官Rachel Leheny博士将于2025年4月9日上午11点PT在Jones Healthcare and Technology Innovation Conference上演讲 [1] - 演讲将进行网络直播，可在公司IR网站“Upcoming Events”部分观看，回放将在公司网站存档90天 [2] 公司概况 - 公司是临床阶段生物制药公司，专注开发用于急慢性炎症和免疫疾病的新型CRAC通道抑制疗法 [1][3] - 公司专有技术通过抑制CRAC通道调节免疫反应，保护组织细胞免受损伤，有望治疗目前无获批疗法的危及生命的炎症和免疫疾病 [3] 产品研发 - 公司领先候选产品Auxora™在多项已完成的疗效临床试验中显示出积极一致的临床结果 [3] - 公司公布了急性胰腺炎（AP）及伴随全身炎症反应综合征（SIRS）患者的2b期试验（CARPO – NCT04681066）数据 [3] - 公司完成了COVID肺炎患者的2期试验（CARDEA – NCT04345614） [3] - 公司正在进行急性肾损伤（AKI）伴急性低氧性呼吸衰竭（AHRF）患者的2期试验（KOURAGE – NCT06374797），预计2025年底出数据 [3] - 公司持续支持小儿天冬酰胺酶诱导的胰腺毒性（AIPT）患者的1/2期试验（CRSPA – NCT04195347），预计2025年下半年有更新 [3] 公司背景 - 公司由Torrey Pines Therapeutics和哈佛CBR生物医学研究所的科学家创立，总部位于加利福尼亚州拉霍亚 [3] 联系方式 - 联系Argot Partners的Kevin Murphy，邮箱[email protected]，电话(212) 600-1902 [4]